Bill Symonds joined Enzyvant as CEO in 2022. Dr. Symonds also serves as the Chief Executive Officer of Altavant Sciences since its inception in August 2018. Previously, Dr. Symonds was a member of the founding management team at Roivant Sciences, Inc. where he served as Roivant’s Chief Development Officer.
In that role, Dr. Symonds crafted the research and development plans for a number of products including rodatristat ethyl, Altavant’s lead asset for the treatment of pulmonary arterial hypertension and was instrumental in the licensing and early development of RETHYMIC®. Earlier in his career, Dr. Symonds held senior positions at a number of pharmaceutical companies including Pharmasset, Inc. and Gilead Sciences, Inc. During his tenure at Pharmasset, Dr. Symonds led the development of Sovaldi® for hepatitis C virus infection medicines. Based on the early success at Pharmasset, Dr. Symonds and his team were brought into Gilead after its acquisition of Pharmasset, where he continued to advance Sovaldi® through to FDA approval. Previously, he worked at GlaxoSmithKline and its predecessor companies on numerous approved medicines for HIV infection including Ziagen®, Agenerase® and Epzicom®.
Dr. Symonds received his Doctor of Pharmacy degree from Campbell University and completed a fellowship in clinical pharmacokinetics at the Clinical Pharmacokinetics Laboratory at Millard Fillmore Hospital in Buffalo, New York. He has authored or co-authored over 35 clinical articles and is named on nine patents related to the composition of matter and methods of use of drugs for hepatitis C infection.
Chief Commercial Officer
As Chief Commercial Officer at Enzyvant, Johanna Rossell provides overall strategic commercial direction for the company and leads U.S. commercialization of RETHYMIC® including marketing, market access and patient support activities. She also provides leadership for Enzyvant growth strategies such as expansions into new geographies, additional indications for the company’s regenerative technology, and new assets.
Johanna has a broad and deep background across consumer goods and healthcare categories, and in several geographies around the world. She has led multifunctional teams delivering strong business results in companies such as Procter & Gamble, Novartis, Merck, Mallinckrodt, and Biogen. She has had extensive success leading new products to market and creating integrated pre-and-post launch commercial plans, including a Regenerative Medicine Advanced Therapy (RMAT)-designated tissue-based product and several therapies for rare diseases.
Johanna received a BS in Computer Engineering and an MBA from Simon Bolivar University in Caracas, Venezuela.
Senior Vice President, Legal
Diane Lifton has served as Enzyvant’s lead corporate attorney since August 2020. She brings more than 25 years of experience providing legal advice to life sciences companies to the role, supporting senior leaders on key areas of drug development, commercialization, compliance, corporate governance, IP portfolio strategy, strategic partnering and business transactions. She holds a Juris Doctorate from the University of Michigan Law School, a Bachelor’s Degree from Cornell University, and a certificate in pharmaceutical law and compliance from Seton Hall Law School’s Health Law Program.
Kevin Healy, PhD, RAC
Senior Vice President, Regulatory Affairs, Pharmacovigilance, and Quality
Kevin Healy is Enzyvant’s Senior Vice President, Regulatory Affairs, Pharmacovigilance, and Quality. In this role, Kevin leads Enzyvant regulatory strategy and execution, including guiding the company’s lead asset, designated as a Regenerative Medicine Advanced Therapy (RMAT), to an FDA approval in 2021. He also is responsible for oversight of pharmacovigilance and quality systems at Enzyvant and partner organizations.
Kevin brings more than a dozen years of biotech and pharmaceutical regulatory affairs experience to his role at Enzyvant. He was the head of Global Regulatory Affairs at Roivant Sciences and led development and successful filings for several therapies in the autoimmune and rare disease portfolio at Mallinckrodt Pharmaceuticals. He also served on global development teams for hepatitis B and C virus treatments at Gilead Sciences.
Kevin received his BS in Biological Sciences from Cornell University, his PhD in Biochemistry from the University of Wisconsin–Madison, and completed a postdoctoral research fellowship in the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill.